TY - JOUR T1 - How often do cancer researchers make their data and code available and what factors are associated with sharing? JF - medRxiv DO - 10.1101/2022.03.10.22272231 SP - 2022.03.10.22272231 AU - Daniel G. Hamilton AU - Matthew J. Page AU - Sue Finch AU - Sarah Everitt AU - Fiona Fidler Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/03/13/2022.03.10.22272231.abstract N2 - Background Various stakeholders are calling for increased availability of data and code from cancer research. However, it is unclear how commonly these products are shared, and what factors are associated with sharing. Our objective was to evaluate how frequently oncology researchers make data and code available, and explore factors associated with sharing.Methods A cross-sectional analysis of a random sample of 306 articles indexed in PubMed in 2019 presenting original cancer research was performed. Outcomes of interest included the prevalence of affirmative sharing declarations and the rate with which declarations connected to useable data. We also investigated associations between sharing rates and several journal characteristics (e.g., sharing policies, publication models), study characteristics (e.g., cancer rarity, study design), open science practices (e.g., pre-registration, pre-printing) and citation rates between 2020-2021.Results One in five studies declared data were publicly available (95% CI: 15-24%). However, when actual data availability was investigated this percentage dropped to 16% (95% CI: 12-20%), and then to less than 1% (95% CI: 0-2%) when data were checked for compliance with key FAIR principles. While only 4% of articles that used inferential statistics reported code to be available (10/274, 95% CI: 2-6%), the odds of reporting code to be available were 5.6 times higher for researchers who shared data. Compliance with mandatory data and code sharing policies was observed in 48% and 0% of articles, respectively. However, 88% of articles included data availability statements when required. Policies that encouraged data sharing did not appear to be any more effective than not having a policy at all. The only factors associated with higher rates of data sharing were studying rare cancers and using publicly available data to complement original research.Conclusions Data and code sharing in oncology occurs infrequently, and at a lower frequency than would be expected due to non-compliance with journal policies. There is also a large gap between those declaring data to be available, and those archiving data in a way that facilitates its reuse. We encourage journals to actively check compliance with sharing policies, and researchers consult community accepted guidelines when archiving the products of their research.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://osf.io/mjuv2 Funding StatementThis research was supported (in part) by the Fetzer Franklin Fund of the John E. Fetzer Memorial Trust. DGH is a PhD candidate supported by an Australian Commonwealth Government Research Training Program Scholarship. MJP is supported by an Australian Research Council Discovery Early Career Researcher Award (DE200101618).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data, materials and code supporting the conclusions of this article are publicly available on the Open Science Framework (DOI: 10.17605/OSF.IO/Z3BFT). https://osf.io/z3bft/ ER -